GMAB genmab.com Net earnings per share growth forecast for next year

Corporate company logo of Genmab Corp (GMAB)

Genmab A/S (GMAB) adheres to basic environmental standards, minimizing the ecological impact of its laboratories. The business relies on DuoBody, creating bispecific antibodies to protect long-term licensing streams. The valuation of forward net income growth rates confirms this potential, where this metric equals 33.60. Financial stability is based on royalties from partners for the implementation of innovative anti-tumor drugs.

GMAB: Genmab AS Net earnings per one share growth forecast for next year 07/04/2022 - 11/10/2026

Financial and market metric breakdowns for genmab.com (GMAB)

- share price and consensus valuation forecast:
Stock Price Genmab US|GMAB - Analyst Consensus Forecast
- market capitalization data:
Market Value Genmab|GMAB - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share Genmab|GMAB - Book Value of Business|Market Capitalization to Book Value Ratio genmab.com|GMAB - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Genmab A/S|GMAB - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Genmab|GMAB - Company Cumulative Debt|Debts to Book Capitalization Genmab|GMAB - Company Long-Term Indebtedness|Company Current Liabilities Genmab|Quick Liquidity Indicator genmab.com
- earnings and valuation multiples information:
GMAB - Profit After Payment of Taxes|Projected Future Earnings Genmab A/S|GMAB - Company Value to Net Income|Forward P/E Multiple Genmab A/S|GMAB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genmab|GMAB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Genmab|GMAB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months genmab.com|GMAB - Earnings per share trend in current year|Expected earnings per share growth for next year Genmab A/S
Fundamental company analysis:Genmab US, GMAB
Brand item of genmab.com

Investors are assessing the potential of Genmab A/S through the dynamics of future earnings. This metric measures the percentage change in expected net income per share for the following year relative to the current year. By analyzing the projected growth of net income per share for year n+1, one can see the calculated value of 33.60. For a biotech company with minimal environmental costs, this indicator reflects the efficiency of antibody development.

Competing companies

EXEL (Exelixis Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year Nuvalent Therapeutics|Net earnings per share growth forecast for next year Kymera Therapeutics (KYMR)|IDYA (ideayabio.com) - Expected earnings per share trend next year|Earnings growth forecast for next year ELVN (Enliven Therapeutics, Inc.)|Net earnings per one share growth forecast for next year ORIC Pharmaceuticals Inc|Relay Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Nurix Corp|TYRA (Tyra Biosciences, Inc.) - Expected earnings per share growth for next year|VSTM: Projected earnings per share increase next year|GLUE (Monte Rosa Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year Cullinan Oncology CGEM|Earnings growth forecast for next year IMRX|C4 Therapeutics Corp - Projected earnings per share growth rate for next year|Black Diamond - Expected earnings per share growth for next year|Expected earnings per share trend next year RPTX|PMVP: Expected earnings per share growth for next year|Karyopharm Therapeutics - Projected earnings per share increase next year|PPCB: Earnings growth forecast for next year|Cyclacel - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aileron ALRN|Net earnings per share growth forecast for next year Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks)